Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won (US$69 million) worth of its own stocks to boost its shareholder value. Celltrion will ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...

Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in its ...

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...

Richard Gonzalez is retiring as chairman of AbbVie. "AbbVie Names CEO Robert Michael Chairman as Richard Gonzales Retires," at 8:20 a.m. ET, misspelled his name as Gonzales in the headline and article ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...